Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

Joy, Melanie S.; Finn, William F.

doi:10.1016/s0272-6386(03)00554-7

Cited by 195 publications

(123 citation statements)

References 13 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Extensive clinical data support its efficacy and tolerability in both short-term (6,7) and long-term (8,9) treatment of hyperphosphatemia in patients with stage 5 CKD. Reformulated (500 mg) and higher strength (750 and 1000 mg) lanthanum carbonate tablets have been available since 2006.…”

mentioning

confidence: 97%

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Mehrotra

Martin

Fishbane

et al. 2008

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Results: At the end of week 4, 54% of patients achieved serum phosphorus control at dosages <3000 mg/d administered as one tablet per meal. Among patients who entered cohort B, control rates of 25, 38, and 32% for patients who were randomly assigned to 3000, 3750, or 4500 mg/d lanthanum carbonate, respectively, were achieved, with no increase in adverse events. Patients and physicians reported significantly higher levels of satisfaction with reformulated lanthanum carbonate compared with previous phosphate binders, partly because of reduced tablet burden with higher dosage strengths. Physicians and patients also expressed a preference for lanthanum carbonate over previous medication.Conclusions: Reformulated lanthanum carbonate is an effective phosphate binder that may reduce daily tablet burden.

show abstract

mentioning

confidence: 97%

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Mehrotra

Martin

Fishbane

et al. 2008

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…There is little doubt that all types of phosphate binders are effective in lowering serum phosphate in dialysis patients when compared to placebo as shown in the systematic review carried out by Navaneethan et al (51). PTH reduction has also been observed with the use of phosphate binders in dialysis patients in some studies (52)(53)(54)(55).…”

Section: Phosphate Bindersmentioning

confidence: 91%

Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Salam

Khwaja

Wilkie

2016

Drugs

View full text Add to dashboard Cite

or Article Brief (if supplied by editors): As a 'Therapy in Practice' article, we would like this to provide a succinct, up-to-date clinically orientated guide to the optimum management of secondary hyperparathyroidism in patients with chronic kidney disease. The review should include an appropriate background to the development of SHPT. It should focus primarily on pharmacological treatments but as appropriate, non-pharmacological approaches (dietary, surgical) may be discussed to fully place pharmacological therapy in context. Submission date: 31 st March 2016Word count: 4156 Compliance with Ethical StandardsFunding and conflict of interest statement from each author: Takeaway messages from the article SHPT is associated with adverse outcomes in CKD and dialysis patients  Optimum PTH level is unclear in pre-dialysis CKD and the recommended range is wide for dialysis patients.  Management of SHPT is largely pharmacological focussing on lowering PTH  PTH lowering treatment has not shown improved cardiovascular risk, fractures and mortality. AbstractSecondary hyperparathyroidism (SHPT) is a common complication of CKD and is part of the chronic kidney disease-mineral bone disorder (CKD-MBD). SHPT is associated with increased risk of fracture and mortality, thus SHPT control is recommended as kidney function declines. Effective SHPT management becomes more difficult once skeletal and cardiovascular adverse effects associated with severe SHPT have become established. However, interventional studies to lower parathyroid hormone (PTH) have so far shown inconsistent results in improving patient-centred outcomes such as mortality, cardiovascular events and fracture. Pharmacological treatment effect on PTH level is also inconsistent between predialysis CKD and dialysis patients which adds to the complexity of SHPT management. This review aims to give an overview on the pathophysiology, pharmacological and non-pharmacological treatment for SHPT in CKD including some of the limitations of current therapeutic options.

show abstract

“…3). Successful control of phosphate is one of the key aspects in the management of dialysis patients (Rodriguez-Benot et al, 2005;Young et al, 2004, Young et al, 2005, However, numerous studies have revealed the difficulty in achieving phosphorus targets less than 5.5 mg/dl (Arenas et al, 2006;Lorenzo et al, 2006: Wei et al, 2006, despite the wide variety of drugs available for its treatment (Joy & Finn, 2003;Sprague, 2007;Arenas et al, 2008). Both endothelial dysfunction and medial calcification are closely associated with development of cardiovascular disease.…”

Section: Combination In Treatmentmentioning

confidence: 99%

Complications and Managements of Hyperphosphatemia in Dialysis

Takeda¹,

Yamamoto²,

Yamanaka-Okumura³

et al. 2011

Progress in Hemodialysis - From Emergent Biotechnology to Clinical Practice

View full text Add to dashboard Cite

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

Cited by 195 publications

References 13 publications

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Higher Strength Lanthanum Carbonate Provides Serum Phosphorus Control With a Low Tablet Burden and Is Preferred by Patients and Physicians

Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Complications and Managements of Hyperphosphatemia in Dialysis

Contact Info

Product

Resources

About